Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin

Item

http://www.wikidata.org/entity/Q42078632

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@en

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@nl

type

Item

label

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@en

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@nl

prefLabel

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@en

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@nl

P1476

Fluoroquinolone resistance in ...... levofloxacin, and moxifloxacin

@en

P2093

Brian Tsuji

http://www.w3.org/2001/XMLSchema#string

Glenn W Kaatz

http://www.w3.org/2001/XMLSchema#string

Kerry L LaPlante

http://www.w3.org/2001/XMLSchema#string

Michael J Rybak

http://www.w3.org/2001/XMLSchema#string

Thomas P Lodise

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.

Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.

The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.

Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes

Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models

Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

P304

1315-1320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00646-06

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6508089

http://www.w3.org/2001/XMLSchema#string

P698

17296740

http://www.w3.org/2001/XMLSchema#string

P921

gatifloxacin

P932

1855487

http://www.w3.org/2001/XMLSchema#string